ABSTRACT
AIM: The aim of the present study was to evaluate the effect of oral caffeine ingestion during repeated sets of resistance. METHODS: Fourteen moderately resistance-trained men (20.9 ± 0.36 years and 77.62 ± 2.07 kg of body weight) ingested a dose of caffeine (5 mg.kg-1) or placebo prior to 3 sets of bench press and 3 sets of leg press exercises, respectively. The study used a double-blind, counterbalanced, crossover design. Repetitions completed and total weight lifted were recorded in each set. Readiness to invest in both physical (RTIPE) and mental (RTIME) effort were assessed prior each set, and rating of perceived exertion (RPE) was recorded after each set. Rest and peak heart rates were determined via telemetry. RESULTS: Caffeine ingestion result in increased number of repetitions to failure in bench press (F[1,13]=6.16, P=0.027) and leg press (F[1,13]=9.33, P=0.009) compared to placebo. The sum of repetitions performed in the 3 sets was 11.60% higher in bench press (26.86 ± 1.74; caffeine: 30.00 ± 1.87; P=0.027) and 19.10% in leg press (placebo: 40.0 ± 4.22; caffeine: 47.64 ± 4.69; P=0.009). Also, RTIME was increased in the caffeine condition both in bench press (F[1,13]=7.02, P=0.02) and in leg press (F[1,13]=5.41, P=0.03). There were no differences in RPE, RTIPE and HR (P>0.05) across conditions. CONCLUSION: Acute caffeine ingestion can improve performance in repeated sets to failure and increase RTIME in resistance-trained men.
Subject(s)
Athletic Performance , Caffeine/administration & dosage , Physical Endurance/drug effects , Resistance Training/methods , Weight Lifting/physiology , Adolescent , Adult , Central Nervous System Stimulants/administration & dosage , Cross-Over Studies , Double-Blind Method , Heart Rate/drug effects , Heart Rate/physiology , Humans , Male , Reference Values , Young AdultABSTRACT
AIM: Investigate, in healthy sedentary rats, the potential mechanisms involved on the effects of beta hydroxy beta methylbutyrate (HMB) supplementation upon the glycaemic homeostasis, by evaluating the insulin sensitivity in liver, skeletal muscle, and white adipose tissue. METHODS: Rats were supplemented with either beta hydroxy beta methylbutyrate (320 mg kg(-1) BW) or saline by gavage for 4 weeks. After the experimental period, the animals were subjected to the glucose tolerance test (GTT) and plasma non-esterified fatty acids (NEFA) concentration measurements. The soleus skeletal muscle, liver and white adipose tissue were removed for molecular (western blotting and RT-PCR) and histological analysis. RESULTS: The beta hydroxy beta methylbutyrate supplemented rats presented: (i) higher ratio between the area under the curve (AUC) of insulinaemia and glycaemia during glucose tolerance test; (ii) impairment of insulin sensitivity on liver and soleus skeletal muscle after insulin overload; (iii) reduction of glucose transporter 4 (GLUT 4) total and plasma membrane content on soleus; (iv) increased hormone-sensitive lipase (HSL) mRNA and protein expression on white adipose tissue and plasma NEFA levels and (v) reduction of fibre cross-sectional area of soleus muscle. CONCLUSION: The data altogether indicate that beta hydroxy beta methylbutyrate supplementation impairs insulin sensitivity in healthy sedentary rats, which, in the long-term, could lead to an increased risk of developing type 2 diabetes.
Subject(s)
Dietary Supplements/toxicity , Insulin Resistance/physiology , Muscle, Skeletal/drug effects , Valerates/toxicity , Adipose Tissue/drug effects , Animals , Blotting, Western , Glucose Tolerance Test , Glucose Transporter Type 4/metabolism , Liver/drug effects , Male , Rats , Rats, Wistar , Real-Time Polymerase Chain ReactionABSTRACT
OBJECTIVE: Beta-hydroxy-beta-methylbutyrate (HMß) is a metabolite of leucine widely used for improving sports performance. Although HMß is recognized to promote anabolic or anti-catabolic effects on protein metabolism, the impact of its long-term use on skeletal muscle and/or genes that control the skeletal protein balance is not fully known. This study aimed to investigate whether chronic HMß treatment affects the activity of GH/IGF-I axis and skeletal muscle IGF-I and myostatin mRNA expression. DESIGN: Rats were treated with HMß (320mg/kg BW) or vehicle, by gavage, for 4 weeks, and killed by decapitation. Blood was collected for evaluation of serum insulin, glucose and IGF-I concentrations. Samples of pituitary, liver, extensor digitorum longus (EDL) and soleus muscles were collected for total RNA or protein extraction to evaluate the expression of pituitary growth hormone (GH) gene (mRNA and protein), hepatic insulin-like growth factor I (IGF-I) mRNA, skeletal muscle IGF-I and myostatin mRNA by Northern blotting/real time-PCR, or Western blotting. RESULTS: Chronic HMß treatment increased the content of pituitary GH mRNA and GH, hepatic IGF-I mRNA and serum IGF-I concentration. No changes were detected on skeletal muscle IGF-I and myostatin mRNA expression. However, the HMß-treated rats although normoglycemic, exhibited hyperinsulinemia. CONCLUSIONS: The data presented herein extend the body of evidence on the potential role of HMß-treatment in stimulating GH/IGF-I axis activity. In spite of this effect, HMß supplementation also induces an apparent insulin resistance state which might limit the beneficial aspects of the former results, at least in rats under normal nutritional status and health conditions.
